The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SHMN | +28.57% | -87.5% | -34.01% | -100% |
| S&P | +12.9% | +73.65% | +11.66% | +406% |
SOHM, Inc. engages in the manufacture and marketing of generic drugs. It develops generic pharmaceuticals in dosage forms, including tablets and capsules, creams and topical, ointments, liquids and injectable. Its products include analgesics, anticancer drugs, antifungals, dermatological, gastrointestinal and respiratory drugs, biotechnology products, immunosuppressive agents, ophthalmic drugs, and treatments for benign prostatic hyperplasia. The company was founded in 1998 and is headquartered in Chino Hills, CA.
No news articles found for Sohm.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $238.43K | 165.2% |
| Gross Profit | $168.96K | 228.7% |
| Gross Margin | 70.86% | 13.7% |
| Market Cap | $945.30K | -64.7% |
| Market Cap / Employee | $85.94K | -64.7% |
| Employees | 11 | 0.0% |
| Net Income | -$47.25K | 71.6% |
| EBITDA | -$46.74K | 71.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $95.67K | 58.4% |
| Accounts Receivable | $99.66K | 0.0% |
| Inventory | 0.5 | 34.5% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.57M | 149.4% |
| Short Term Debt | $0.00K | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.24% | 36.8% |
| Return On Invested Capital | 91.31% | -267.2% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.25K | 97.6% |
| Operating Free Cash Flow | -$2.25K | 97.6% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -3.24 | 25.00 | 23.33 | 20.00 | -370.59% |
| Price to Sales | 3.39 | 3.09 | 1.47 | 1.10 | -82.16% |
| Price to Tangible Book Value | -3.28 | 24.97 | 27.85 | 23.87 | -425.00% |
| Price to Free Cash Flow TTM | 736.13 | 13.10 | - | ||
| Enterprise Value to EBITDA | 70.86 | -139.53 | -12.12 | -121.69 | 349.41% |
| Free Cash Flow Yield | 0.1% | 7.6% | - | ||
| Total Debt | $1.78M | $1.83M | $4.36M | $4.57M | 149.41% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
